A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

Inclusion Criteria: * Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive medication Exclusion Criteria: * Secondary hypertension, orthostatic hypotension * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2× upper limit of normal (ULN) * Elevated potassium \>5 mEq/L * Estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73m\^2 * Received an investigational agent within the last 30 days * Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, newly diagnosed Type 2 diabetes mellitus * History of any cardiovascular event within 6 months prior to randomization * History of intolerance to SC injection(s)